John L. Mershon

3.3k total citations · 1 hit paper
40 papers, 2.5k citations indexed

About

John L. Mershon is a scholar working on Genetics, Oncology and Cancer Research. According to data from OpenAlex, John L. Mershon has authored 40 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 16 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in John L. Mershon's work include Estrogen and related hormone effects (20 papers), Cancer Risks and Factors (15 papers) and Breast Cancer Treatment Studies (8 papers). John L. Mershon is often cited by papers focused on Estrogen and related hormone effects (20 papers), Cancer Risks and Factors (15 papers) and Breast Cancer Treatment Studies (8 papers). John L. Mershon collaborates with scholars based in United States, United Kingdom and Germany. John L. Mershon's co-authors include Nira Ben‐Jonathan, Donald L. Allen, Rosemary Steinmetz, Silvana Martino, Damon Disch, Trevor J. Powles, Jane A. Cauley, Steven R. Cummings, Trong Kim Le and Russel Burge and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Endocrine Reviews.

In The Last Decade

John L. Mershon

39 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects*

1996 590 citations Nira Ben‐Jonathan, John L. Mershon et al. Endocrine Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John L. Mershon United States	22	1.0k	778	533	532	401	40	2.5k
Yoko Yamamoto Japan	24	593 0.6×	1.0k 1.3×	290 0.5×	1.4k 2.6×	391 1.0×	49	3.0k
Mark B. Meyer United States	38	885 0.9×	883 1.1×	373 0.7×	2.2k 4.2×	337 0.8×	82	4.9k
Vanessa Dubois Belgium	22	428 0.4×	306 0.4×	555 1.0×	1.0k 1.9×	130 0.3×	41	2.3k
Toshio Tsushima Japan	33	498 0.5×	584 0.8×	2.1k 3.9×	1.2k 2.2×	253 0.6×	119	3.7k
A. Ederveen Netherlands	28	670 0.7×	336 0.4×	373 0.7×	716 1.3×	79 0.2×	58	2.0k
Atsushi Imai Japan	26	323 0.3×	310 0.4×	228 0.4×	845 1.6×	168 0.4×	158	2.4k
Graeme R. Frank United States	16	1.4k 1.4×	376 0.5×	1.0k 1.9×	943 1.8×	63 0.2×	35	3.0k
Hideo Honjo Japan	30	856 0.8×	264 0.3×	359 0.7×	476 0.9×	109 0.3×	111	3.3k
Martina Weise Germany	22	328 0.3×	297 0.4×	640 1.2×	845 1.6×	109 0.3×	39	2.4k
Teresa García Spain	25	557 0.6×	818 1.1×	213 0.4×	882 1.7×	293 0.7×	61	2.3k

Countries citing papers authored by John L. Mershon

Since Specialization

Citations

This map shows the geographic impact of John L. Mershon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Mershon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Mershon more than expected).

Fields of papers citing papers by John L. Mershon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Mershon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Mershon. The network helps show where John L. Mershon may publish in the future.

Co-authorship network of co-authors of John L. Mershon

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Mershon. A scholar is included among the top collaborators of John L. Mershon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Mershon. John L. Mershon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Elborn, J.S., Michael W. Konstan, Jennifer L. Taylor‐Cousar, et al.. (2021). Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. Journal of Cystic Fibrosis. 20(6). 1026–1034. 11 indexed citations

Elborn, J.S., Sanjeev Ahuja, Eric B. Springman, et al.. (2018). EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis – Study design and patient demographics. Contemporary Clinical Trials. 72. 86–94. 25 indexed citations

Le, Trong Kim, et al.. (2013). Tibia shaft fractures: costly burden of nonunions. BMC Musculoskeletal Disorders. 14(1). 42–42. 273 indexed citations

Meadows, Eric S., et al.. (2011). Compliance with mammography and bone mineral density screening in women at least 50 years old. Menopause The Journal of The North American Menopause Society. 18(7). 794–801. 6 indexed citations

Goldstein, Steven R., Claire S. Duvernoy, Joaquím Calaf, et al.. (2009). Raloxifene use in clinical practice. Menopause The Journal of The North American Menopause Society. 16(2). 413–421. 30 indexed citations

Vogel, Victor G., Yongming Qu, Mayme Wong, Beth Mitchell, & John L. Mershon. (2009). Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration. Clinical Breast Cancer. 9(1). 45–50. 11 indexed citations

Grady, Deborah, Jane A. Cauley, Margarethe Geiger, et al.. (2008). Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk. JNCI Journal of the National Cancer Institute. 100(12). 854–861. 44 indexed citations

Mershon, John L., Margarethe Geiger, E. Barrett-Connor, et al.. (2007). Effect of coronary heart disease (CHD) risk factors and medications on invasive breast cancer risk in the Raloxifene Use for The Heart (RUTH) trial. Journal of Clinical Oncology. 25(18_suppl). 1530–1530.

Cauley, Jane A., Jingli Song, Sherie A. Dowsett, John L. Mershon, & Steven R. Cummings. (2006). Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Research and Treatment. 102(2). 181–188. 26 indexed citations

10.

Baker, Richard S., et al.. (2006). Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep. American Journal of Physiology-Heart and Circulatory Physiology. 291(3). H1216–H1225. 5 indexed citations

11.

Martino, Silvana, Jane A. Cauley, Elizabeth Barrett‐Connor, et al.. (2004). Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. JNCI Journal of the National Cancer Institute. 96(23). 1751–1761. 487 indexed citations

12.

Martino, Silvana, Joseph P. Costantino, Michelle McNabb, et al.. (2004). The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials. The Oncologist. 9(2). 116–125. 31 indexed citations

13.

Martino, Silvana, Jane A. Cauley, E. Barrett-Connor, et al.. (2004). Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. Journal of Clinical Oncology. 22(14_suppl). 1000–1000. 3 indexed citations

14.

Baker, Richard S., et al.. (2002). Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine. American Journal of Obstetrics and Gynecology. 187(6). 1555–1560. 4 indexed citations

15.

Buchbinder, Alan, et al.. (2001). Leptin in the ovine fetus correlates with fetal and placental size. American Journal of Obstetrics and Gynecology. 185(4). 786–791. 27 indexed citations

16.

Mershon, John L., et al.. (2001). Estrogen receptor β is the predominant isoform expressed in the brain of adult and fetal sheep. American Journal of Obstetrics and Gynecology. 184(6). 1077–1079. 4 indexed citations

17.

Ben‐Jonathan, Nira, John L. Mershon, Donald L. Allen, & Rosemary Steinmetz. (1996). Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects*. Endocrine Reviews. 17(6). 639–669. 590 indexed citations breakdown →

18.

Mershon, John L., Gábor Mikala, & Arnold Schwartz. (1994). Changes in the Expression of the L-Type Voltage-Dependent Calcium Channel during Pregnancy and Parturition in the Rat1. Biology of Reproduction. 51(5). 993–999. 48 indexed citations

19.

Watanabe, Toshiro, Huba Kalász, Hideo Yabana, et al.. (1993). Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the α₁ subunit of the skeletal muscle calcium channel. FEBS Letters. 334(3). 261–264. 32 indexed citations

20.

Kniss, Douglas A., John L. Mershon, Jiri Sonek, et al.. (1990). Evidence of a role for protein kinase C in epidermal growth factor-induced prostaglandin E2 synthesis in amnion cells. American Journal of Obstetrics and Gynecology. 163(6). 1883–1890. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact